Notification: Due to a country-wide Canada Post strike, shipments are on hold until further notice. We apologize for the inconvenience.

Call Toll Free 1- 888-779-2193

SAVE 10% OFF on First Order with Coupon Code: WELCOMEPB10

Call Toll Free 1- 888-779-2193

SAVE 10% OFF on First Order with Coupon Code: WELCOMEPB10

FDA Approves Trelegy Ellipta for the Treatment of COPD and Asthma

Trelegy Ellipta for COPD & Asthma Treatment

Asthma, along with COPD, known as Chronic Obstructive Pulmonary Diseases are respiratory conditions that make breathing difficult. While asthma results in swollen and sensitive airways, COPD comprises a group of disorders that arise from lung damage and airway irritation. As mentioned in the National Library of Medicine, approximately 15% of adults in the USA are affected by respiratory problems like asthma and COPD. 

These statistics highlight the significance of the FDA’s approval for theTrelegy Ellipta inhaler, which is aimed at managing these chronic conditions across the USA. For those looking to manage their respiratory conditions effectively, you can buy Trelegy Ellipta online. So, in this blog, we will explore why the FDA approves Trelegy Ellipta in the treatment of asthma and COPD and explore the safety information regarding these inhalers.

Why FDA Approves the Trelegy Ellipta for Treating COPD and Asthma?

Being the first single inhaler with triple therapy targeting multiple pathways involved in the inflammatory process and bronchoconstriction, Trelegy GSK (Trelegy inhaler) provides effective symptom relief and enhances lung function in patients with COPD and asthma. As a result, the FDA approved the use of Trelegy Ellipta inhalers to treat asthma in patients aged 18 years. As mentioned in GSK’s press release, this decision brings new treatment options to around 30% of asthma patients who still experience symptoms despite using a combination therapy of inhaled corticosteroids and long-acting beta-agonists.

Moreover, developed by GSK (GlaxoSmithKline), the Trelegy inhaler is manufactured by combining three active ingredients: fluticasone, umeclidinium, and vilanterol.

  • Fluticasone: It is a steroid that prevents the release of substances in the body, causing inflammation. 
  • Umeclidinium: Functioning as an anticholinergic agent, umeclidinium aids in relaxing the airway’s muscles, thereby improving respiration and reducing bronchospasms.
  • Vilanterol: This ingredient is a long-acting bronchodilator that works by soothing muscles in the airways over an extended period, facilitating smoother breathing.

All these ingredients are helpful for the treatment of respiratory problems like COPD and asthma, thus contributing to the FDA’s approval of the Trelegy inhaler. 

Effectiveness of Trelegy Ellipta Inhaler: Clinical Evidence

The Trelegy inhaler, a combination therapy consisting of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI), represents a major advancement in the management of moderate to severe asthma. The Clinical Study of Asthma Patients Receiving Triple Therapy in a Single Inhaler (CAPTAIN) provides important insights into its efficacy. This study recruited 2,436 patients from 15 countries and randomly assigned them to different treatment groups. 

The CAPTAIN study found that FF/UMEC/VI significantly improved lung function and breathing in individuals with asthma, which was not well-controlled by standard inhaled corticosteroid and long-acting β2-agonist (ICS/LABA) therapy. Moreover, it did offer a safer and more effective treatment alternative for these patients.

By targeting multiple pathways involved in asthma pathology, Trelegy Ellipta helps in providing symptom relief and enhances the quality of life for individuals with complicated asthma symptoms. These results highlight the importance of triple therapy inhalers like Trelegy Ellipta for managing more complicated asthma cases where regular treatments are not enough.

Benefits of Triple Therapy Inhaler for Asthma & COPD Patients

Trelegy Ellipta inhaler provides asthma and COPD patients with a number of benefits, which are as follows:

  • Target Multiple Pathways: Triple therapy typically consists of an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA). This combination targets multiple pathways involved in asthma and COPD, leading to improved symptom control.
  • Reduced Exacerbations: By providing comprehensive treatment that targets both inflammation and bronchoconstriction, triple therapy helps stabilize the airways and minimize the risk of exacerbations, thereby improving disease management and reducing healthcare utilization. 
  • All-in-One Triple Therapy Inhaler: Combining fluticasone, umeclidinium, and vilanterol into a single inhaler makes treatment easier for asthma and COPD patients. This simple approach improves adherence and effectively manages both inflammation and bronchoconstriction.
  • Improved Lung Function: The combination of an ICS, LABA, and LAMA work together to help widen the airways and lower inflammation, leading to better lung function. Patients treated with triple treatment often experience improvements in their pulmonary function tests, which are indicative of better respiratory health.

By targeting multiple aspects of these complex respiratory conditions, triple therapy inhalers not only improve patients’ quality of life but also provide a convenient solution for those looking to buy Trelegy inhaler. 

Warnings and Precautions for Trelegy GSK

  • Trelegy does not provide immediate relief from breathing problems. If you experience severe symptoms, use a short-acting beta2-agonist inhaler.
  • Avoid using the inhaler frequently or in higher doses than prescribed. Do not combine it with other LABAs (Long-Acting Beta-Agonists), as this can lead to overdose and serious cardiovascular issues.
  • Patients switching from systemic corticosteroids to triple therapy should do so gradually, as sudden changes can cause adrenal insufficiency and potentially fatal outcomes.
  • Taking higher doses of the triple therapy inhaler may cause hypercorticism and adrenal suppression. If such effects occur, slowly reduce the dosage and explore alternative treatments.
  • This inhaler may cause hypersensitivity reactions in some people. If you experience any of these symptoms, discontinue use immediately.
  • Patients with narrow-angle glaucoma should use this inhaler cautiously and seek medical help if they notice signs of acute narrow-angle glaucoma.
  • The product is not recommended for use by children and teenagers. There is no clinical evidence that supports the safety and effectiveness of the inhaler in pediatric patients (aged 17 years and younger).
  • Be cautious while using Trelegy in patients with moderate or severe liver problems, as it may increase the amount of fluticasone furoate in the body by up to three times.

So, if you are thinking to order drugs from Canada, always trust reputable online pharmacies such as Polar Bear Meds, the best Canadian online pharmacy. With our quick and easy order process, you will receive quality medications in just 3-5 business days.

Conclusion

The FDA’s approval of the Trelegy Ellipta inhaler marks a major advancement in the treatment of COPD and asthma. With successful clinical trials, this triple inhaler, which combines 3 active ingredients- fluticasone, umeclidinium, and vilanterol, revolutionizes the medical industry with its effective results. From symptom control to simplified treatment regimens, the FDA-approved triple therapy Trelegy inhaler offers several benefits to patients suffering from asthma and COPD. However, while the inhaler shows promising results, it is important for patients to be aware of its warnings and precautions. In the end, Trelegy Ellipta is a big step forward in respiratory care, offering complete support and making life easier for people with severe breathing problems.

Scroll to Top